Eton Pharmaceuticals grants CFO 32,246 performance RSUs
Eton Pharmaceuticals, Inc. reported that Chief Financial Officer Judith M. Matthews received a grant of 32,246 performance-vested restricted stock units under the company's 2018 equity incentive plan.
Rhea-AI Filing Summary
Eton Pharmaceuticals, Inc. reported that Chief Financial Officer Judith M. Matthews received a grant of 32,246 performance-vested restricted stock units under the company's 2018 equity incentive plan. Each unit represents the right to acquire one share of common stock.
The award vests in full only if the closing price of Eton's common stock equals or exceeds $72.36 per share for one trading day at any time before July 31, 2029; if this market condition is not satisfied, the entire award is forfeited without consideration. The filing characterizes the transaction as a grant or award acquisition rather than an open-market purchase.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 32,246 shares
Grant/Award
1 txn
Insider
Matthews Judith M.
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 32,246 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 32,246 contracts (Direct)
Footnotes (1)
- F1. On July 31, 2026, the reporting person was granted 32,246 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.
Key Figures
Performance-vested RSUs granted: 32,246 units
Market vesting price condition: $72.36 per share
Award forfeiture date: July 31, 2029
+2 more
5 metrics
Performance-vested RSUs granted
32,246 units
Grant to CFO Judith M. Matthews on July 31, 2026 under the 2018 equity incentive plan
Market vesting price condition
$72.36 per share
Closing price required for one trading day for the RSUs to vest in full
Award forfeiture date
July 31, 2029
Date on which the award is forfeited in its entirety if the market condition is not met
Share-to-unit ratio
1 share per unit
Each restricted stock unit represents the right to acquire one share of common stock
Trading days required
1 trading day
Stock must close at or above $72.36 for one trading day to satisfy the vesting condition
Key Terms
performance-vested restricted stock units, equity incentive plan, market condition, forfeited in its entirety
4 terms
performance-vested restricted stock units financial
"the reporting person was granted 32,246 performance-vested restricted stock units granted"
equity incentive plan financial
"restricted stock units granted under the Issuer's 2018 equity incentive plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
market condition financial
"If this market condition is not satisfied prior to such date, the award will be forfeited"
forfeited in its entirety financial
"the award will be forfeited in its entirety without consideration on July 31, 2029"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Eton Pharmaceuticals (ETON) report for CFO Judith M. Matthews?
Eton Pharmaceuticals reported that CFO Judith M. Matthews received a grant of 32,246 performance-vested restricted stock units. The award was issued under the 2018 equity incentive plan and is contingent on a specified stock price condition before July 31, 2029.
How many restricted stock units were granted to the ETON CFO in this Form 4?
The CFO was granted 32,246 performance-vested restricted stock units. Each unit represents the right to acquire one share of Eton Pharmaceuticals common stock, with vesting dependent on meeting a market-based stock price condition by July 31, 2029.
What is the vesting condition on Judith M. Matthews' RSU award at Eton Pharmaceuticals (ETON)?
The RSU award vests only if Eton's stock closing price reaches at least $72.36 per share for one trading day. This market condition must be satisfied at any time before the third anniversary of the grant date, which corresponds to July 31, 2029.
What happens to the 32,246 performance-vested RSUs if ETON's stock does not hit the price condition?
If the $72.36 per share market condition is not achieved for one trading day before July 31, 2029, the entire 32,246-unit award will be forfeited without consideration on July 31, 2029, and no shares will be delivered under this grant.
Were the ETON CFO's reported RSUs part of an open-market buy or a compensation grant?
The transaction is reported as a grant or award acquisition, not an open-market stock purchase. The units were granted at a price of $0.00 per unit under Eton Pharmaceuticals' 2018 equity incentive plan, with vesting tied to a specified stock price condition.
AI-generated analysis. How Rhea-AI works. Not financial advice.
